Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a multicenter phase 2 clinical trial to investigate the treatment efficacy and
feasibility of combining thoracic radiotherapy (TRT) with the IMpower133 regimen in the
upfront treatment of ED SCLC patients. Patients with a response after induction therapy with
carboplatin/etoposide and atezolizumab will be included into this study to subsequently
receive atezolizumab maintenance therapy and will be randomized to receive TRT or not. This
trial aims to i.) increase the efficacy of combined atezolizumab- and chemotherapy by adding
radiotherapy and ii.) determine the safety and tolerability of the combination of
chemotherapeutic, immunological and radiological treatment in the first-line setting of
advanced SCLC, and iii.) to collect tumor tissue as well as blood and stool samples for
separate biomarker research project.
Phase:
Phase 2
Details
Lead Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest